Metal complexes in medicine with a focus on enzyme inhibition.
Since the clinical success of cisplatin and its derivatives, considerable effort has been expended by academics and pharmacological companies to the development of novel metal-based drugs. DNA is believed to be the main target of cisplatin, and there have been extensive studies on the binding between metal complexes and DNA targets. Recently, new light has been shed on the discovery of metal-based drugs that inhibit enzymatic activities or even target proteins directly. This review highlights some exciting results published recently on the development of platinum, gold, and ruthenium complexes as enzyme inhibitors for potential therapeutic applications.
Che
Chi-Ming
CM
Department of Chemistry and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong, China. cmche@hku.hk
Siu
Fung-Ming
FM
D000818:Animals; D056831:Coordination Complexes / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017612:Gold Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D017671:Platinum Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D017975:Ruthenium Compounds / Q000494:pharmacology* / Q000627:therapeutic use
D056831:Coordination Complexes; D004791:Enzyme Inhibitors; D017612:Gold Compounds; D017671:Platinum Compounds; D017975:Ruthenium Compounds